Development and Drug Delivery in Epigenetic Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 43
Special Issue Editor
Interests: drug design; drug discovery; pharmacophore; drug delivery; organic synthesis; drug cell–membrane permeability; pharmaceutical sciences; medicinal chemistry; chemical biology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We will be serving as Guest Editors for this very interesting Special Issue on “Development and Drug Delivery in Epigenetic Therapy”. Epigenetics plays a vital role in regulating DNA without altering the underlying DNA sequence. Epigenetic regulation occurs through DNA methylation, histone modifications, and interactions with non-coding RNAs, including miRNAs, piRNAs, siRNAs, and long non-coding RNAs. DNA methylation suppresses gene expression, while histone modifications include acetylation, methylation, phosphorylation, and ubiquitylation. Currently, a range of epigenetic drugs, including histone deacetylase inhibitors, have been developed for the treatment of various conditions, such as cancers, central nervous system disorders, and cardiovascular diseases. However, many of these agents face challenges related to solubility, stability, and membrane impermeability. Nanodelivery systems, drug conjugates, and prodrugs may provide promising solutions to these issues. This Special Issue aims to highlight recent progress and emerging trends in this field. We welcome submissions of original research articles focused on the development of epigenetic drugs.
Topics include, but are not limited to, the strategies outlined below.
As targets of epigenetic modulators:
- DNA methyltransferases;
- Histone deacetylases (HDACs);
- Histone acetyltransferases (HATs);
- Histone lysine methyltransferases (HKMTs);
- Histone lysine demethylases such as lysine demethylase 1 (KDM1 or LSD1) and the Jumonji C-terminal domain (JmjC) family of histone demethylases;
- Bromodomain and extra-terminal (BET) proteins;
- Non-coding RNAs.
As epigenetic drug delivery:
- Nanoparticles;
- Prodrugs;
- Conjugates with vectors such as cell-penetrating peptides, antibodies, and tumor-homing peptides.
As target diseases:
- Cancers;
- Central nervous system diseases;
- Cardiovascular disease.
Dr. Toshihiko Tashima
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epigenetics
- epigenetic drugs
- histone deacetylase inhibitors
- cancers
- central nervous system diseases
- histone modifications
- non-coding RNAs
- drug delivery system
- nanodelivery
- drug conjugates
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
